Veelken Hendrik
Department of Hematology/Oncology, Freiburg University Medical Center, Hugstetter Strasse 55, D-79106 Freiburg, Germany.
Semin Cancer Biol. 2003 Jun;13(3):241-7. doi: 10.1016/s1044-579x(03)00020-8.
The antigen receptors expressed by follicular lymphomas represent tumor-specific antigens ("idiotypes"). In murine models, vaccination with tumor-derived idiotype in a variety of formulations can induce protective lymphoma-specific immunity. Phase II clinical trials in follicular lymphoma have also demonstrated idiotype-specific immune responses. Clinical data from these trials indicate sustained progression-free survival, disappearance of minimal residual disease, and even frank lymphoma regression in some cases. Phase III trials to prove the beneficial effects of active immunotherapy are currently being conducted. Additional research efforts focus on the most efficacious vaccination route and on the development of convenient methods to manufacture individual idiotype vaccines.
滤泡性淋巴瘤表达的抗原受体代表肿瘤特异性抗原（“独特型”）。在小鼠模型中，用多种制剂的肿瘤衍生独特型进行疫苗接种可诱导保护性淋巴瘤特异性免疫。滤泡性淋巴瘤的II期临床试验也证明了独特型特异性免疫反应。这些试验的临床数据表明，患者无进展生存期持续延长，微小残留病消失，在某些情况下甚至出现明显的淋巴瘤消退。目前正在进行III期试验以证明主动免疫疗法的有益效果。其他研究工作集中在最有效的疫苗接种途径以及开发方便的方法来生产个性化独特型疫苗。
